jefffrankelmd

8/14/2019 JeffFrankelMD

1/6

Curriculum Vitae For:Jeffrey Marc Frankel, MD

Jeffrey Marc Frankel, MD

16259 Sylvester Road Southwest, Suite 303

Seattle, WA 98166

Office Phone: 206.244.2822Office Fax: 206.243.7807

Credentials:

Medical License: Washington MD00022889

Diplomate: American Board of Medical Examiners

Certification: American Board of Urology, 1987, Re-certified, 1995, 2005

Education:

1971 1975 BS Biology/Psychology, University of Washington, Seattle,

Washington

1975 1979 MD University of Washington, Seattle, Washington

1979 1980 Internship: San Diego Veterans Administration Hospital Surgery, La

Jolla, California

1979 1980 Internship: University Hospital, San Diego, California

1980 1981 Residency: City of Hope Hospital, Durante, California

1980 1981 Surgical Residency: San Diego Veterans Administration Hospital, La Jolla,

California

1980 1981 Residency: University Hospital, San Diego, California

1981 1985 Urology, Baylor College of Medicine Affiliated Hospitals, Houston,

Texas

Endourology and Extracorporeal Shock Wave LithotripsyGenitourinary Prosthetics

Microvascular Surgery (80 hour instructional course)

Work Experience:

2005 - Present Medical Director Seattle Urology Research Center

1991 Present Clinical Research: Principal and Sub Investigator

1988 Present Physician Private Practice Urology; 16259 Sylvester Road

Southwest, Suite 303, Seattle, Washington

1985 1987 Private Urology Practice Kent Medical Center, Kent, Washington

Hospital Affiliations:

1987 Present Active Staff, Highline Medical Center, Seattle, Washington1985 Present Active Staff, Valley Medical Center, Kent, Washington

1985 2000 Active Staff, Virginia Mason Hospital, Seattle, Washington

September 2007 1


2/6


Board of Director Affiliations:

03/15/2009-03/21/2010 President, American Association of Clinical Urologists (AACU)

01/01/2008-12/31/2009 Chief of Staff Highline Medical Center

01/01/2006-12/31/2007 President Elect Highline Medical Center

01/01/2006 Present Board of Trustees: Highline Medical Center

03/30/2008-03/31/2009 President Elect, American Association of Clinical Urologists

03/2005 Present Board of Directors Western Region Representative America Association

of Clinical Urologist

2005 2006 President, Washington State Urological Society, Washington

2005 Present Medical Director, Seattle Urology Research Center

2004 2005 Secretary/Treasurer, Medical Executive Committee, Highline

Medical Center

2003 2004 President Elect, Washington State Urological Society, Washington

2000 2002 Board of Directors, Western Section, American Urological Association

1995 1996 Board of Directors, Highline Medical Service Organization

Seattle, Washington1994 1995 Board of Directors, Highline Hospital Foundation, Seattle,

Washington

1993 1995 Chief of Surgery, Highline Medical Center, Seattle, Washington

Professional Affiliations

Active Member, Washington State Urological Society

Active Member, Northwest Urological Association

Active Member, King County Medical Society

Active Member, American Urological Association, Western Section

Active Member, American Urological Association

Active Member, American Association of Clinical UrologistsResearch Activities:

1. A two Phase, Double-Blinded, Randomized, Parallel-Group Design, MulticenterStudy Of XXXXX Versus XXXXX In Male Patients With Acute Urinary

Retention Related To Benign Prostatic Hyperplasia

2. A long-Term, Open-Label Clinical Study Evaluating the Safety and Efficacy of

XXXXX in Subjects with Symptomatic Benign Prostatic Hyperplasia (BPH).

3. A Multi-Center, Multi-Market Survey To Evaluate The Potential Enrollment Rate

Using a Media-Based Recruitment Program In A Population Of Men Aged Greater

Than 40 Years With Mild To Moderate Signs And Symptoms Of Benign Prostatic

Hyperplasia.

September 2007 2


3/6


4. A Double-Blind, Randomized, Parallel Group Trial of XXXXX ExtendedRelease Tablets or Placebo In Combination with XXXXX For the Treatment Of

Lower Urinary Tract Symptoms (Protocol CAPSS-292)

5. A Multi-Center, Double-Blind, Double-Dummy, Randomized, Placebo And

XXXXX Controlled Parallel Group Study To Assess The Efficacy And Safety Of

XXXXX In Subjects With Lower Urinary Tract Symptoms Due To Benign

Prostatic Obstruction

6. Long-Term Efficacy And Safety Of XXXXX On The Risk Of Acute UrinaryRetention And The Need For Surgery In Patients With BPH. A Two-Year,

Randomized, Multicenter, Double-Blind, Parallel Group, Placebo-Controlled Study

7. A Phase II/III, Double-Blind, Placebo Controlled, Dose-Finding Study Of The

Safety And Efficacy Of XXXXX In Patients With Symptomatic Benign Prostatic

Hyperplasia (BPH).

8. A Double-Blind Placebo-Controlled, Parallel-Group Safety and Efficacy Study

Evaluating Three Dose Regiments Of XXXXX, A Selective Alpha-Adrenergic

Antagonist, In The Treatment Of Benign Prostatic Hyperplasia

9. An Eleven-Week, Open-Label, Randomized, Multicenter, Parallel-Design, Placebo

Lead-In Study Of XXXXX Capsules, 0.4mg Daily Versus XXXXX Capsules, 5mg

(With XXXXX) Daily In Patients With The Signs And Symptoms Of Benign

Prostatic Hyperplasia.

10. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Fixed-Dose,

Parallel Group, 6-Month Comparison Study To Investigate The Efficacy and SafetyOf XXXXX In Males With Erectile Dysfunction

11. A Randomized, Double-Blind, Parallel, Placebo-Controlled Study In Men With

Erectile Dysfunction To Evaluate The Efficacy And Safety Of XXXXX When Sexual

Attempts Occur At Specific Time Points After Dosing

12. An Open-Label, Non-Controlled, Fixed-Dose, Sequential Dose-Ranging Study To

Evaluate The Safety, Tolerance, Pharmacokinetics And Hormonal Efficacy Of

Monthly Doses Of XXXXX In Patients With Advanced Prostate Cancer

13. An Open-Label, Randomized, Multi-Center, Parallel Group Comparison Of The

Efficacy And Safety Of XXXXX At Two Different Dosing Regiments In Patients

With Prostate Cancer Dosed For Thirteen 28-day Cycles

14. A Phase II Study Evaluating The Safety And Efficacy Of XXXXX In Men With

Hormone Nave Prostate Cancer That Are Exhibiting Early Signs Of Biochemical

Failure.

15. A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety

And Efficacy Of XXXXX mg XXXXX In Men With Metastatic, Hormone-

Refractory Prostate Cancer

16. A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety

And Efficacy Of XXXXX mg XXXXX In Men With Non-Metastatic, Hormone-

Refractory Prostate CancerSeptember 2007 3


4/6


17. A Phase III Extension Study To Evaluate The Safety Of XXXXX mg XXXXX In

Men With Hormone-Refractory Prostate Cancer.

18. Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To

Assess The Safety And Efficacy Of XXXXX In Delaying The Systemic

Progression Of Prostate Cancer In Patients With Intermediate To High Risk Of

Recurrence With Rising Prostate Specific Antigen (PSA) Levels After

Prostatectomy, Prostatectomy And Radiotherapy, Or Radiotherapy Alone For

Localized Disease

19. A Phase III, Randomized Mulitcenter, Placebo-Controlled, Double-blind ClinicalTrial To Study The Efficacy And Safety Of XXXXX For The Treatment Of Hot

Flashes Following Surgical Or Chemical Castration Of Prostate Cancer Patients

And Its Impact On The Quality Of Life In These Patients

20. A Randomized Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose,

Multicenter Study To Assess Efficacy And Safety Of Daily Oral Administration

of XXXXX Versus Placebo In Male And Female Subjects With Overactive

Bladder

21. An Open-Label, Long Term Tolerability Study Of Daily Oral Administration Of

XXXXX In Male And Female Subjects With Overactive Bladder

22. A 6-Week, Double-Blind, Placebo Controllekd, Randomized, Parallel Group,Multicenter, Multidose Study Of The Efficacy And Safety Of XXXXX In Patients

With Overactive Bladder Symptoms Of Increased Urinary Frequency, Urgency, And

Urge Incontinence

23. Study Of XXXXX In Women Of Different Demographic Characteristics And

Co morbidities With Stress Urinary Incontinence: Evaluation Of Efficacy And Safety

24. McNeil Consumer & Specialty Pharmaceuticals, A Placebo-Controlled Study

Evaluating The Safety And Efficacy Of XXXXX 3mg And 5mg In Women With

Overactive Bladder

25. Double-Blind, Placebo Controlled Study Of XXXXX In Subjects With

Symptoms Of Overactive Bladder Of Urgency, Frequency And Urinary Incontinence

26. Open-Label Extension Study Of Sustained Release XXXXX In Subjects With

Symptoms Of Overactive Bladder

27. A Double-Blind, Placebo-Controlled, Randomized US Study To Evaluate The

Effect Of XXXXX On Nocturia In Patients With Symptoms Of Overactive Bladder

28. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study ComparingXXXXX Transdermal Systems Versus XXXXX Long Acting Capsules In Patients

With Overactive Bladder

29. A Dose-Range Study To Evaluate XXXXX, XXXXX, And XXXXX WhenSeptember 2007 4


5/6


Administered To Female Subjects With Unstable Bladder Conditions

30. XXXXX In Patients With Urge Urinary Incontinence: A 12-Week Multi-Center,Randomized, Double-Blind, Placebo-Controlled Study With A 12-Week Open-

Label, Dose-Titration, Safety Extension.

31. Prospective, Randomized, Double-Blind Multi-Center, Comparative Trial To

Evaluate The Efficacy And Safety Of XXXXX Once-Daily (QD) Modified Release

(XXXXX MR) Tablets 1000Mg Conventional XXXXX 500 Mg Tablets In The 7-

14 Day Treatment Of Patients With Complicated Urinary Tract Infections (cUTI)

Or Acute, Uncomplicated Pyelonephritis

32. A Multi-Center, Randomized, Double blind, Placebo Controlled, Parallel Evaluation ofthe Efficacy and Safety of xxxxxxxx in the treatment of the Signs and Symptoms of

Benign Prostatic Hyperplasia.

33. A Multi-Center Open Label Evaluation of the Safety of xxxxxxxxx in the Treatment of

the Symptoms of Benign Prostatic Hyperplasia.

34. An Open Label Multi-Center, Randomized, Parallel-Group study Investigating, the

Efficacy and Safety of xxxxxxxx on Month dosing regimen in comparision to xxxxxx

Depot, in patients with prostate cancer requiring Androgen Ablation Therapy.

\

35. An Open Label , Multi-Center Extension Study, Investigating Long Term Safety and

Tolerability of xxxxxxxxx one month Depots in Patients with Prostate Cancer.

36. A Phase 2, Randomized , Multi-Center, Placebo-Controlled, Double-Blind, Dose

Treatment of Hot Flashes following Surgical or Medical Castration of Prostate.

37. A Multicenter , Double-Blind, Placebo controlled, Flexible- Dose Study with an OpenLabel Phase to asses the Efficacy of xxxxxxxxxxx xxxxxxx On Erectile Function and

intercourse satisfaction as well as to Validate the Sexual experience Questionnaire and its

Treatment Responsiveness in man with Erectile Dysfunction.

38. A Randomized, Double-Blind Placebo-Controlled, Multi-Center Phase 3 of xxxxxxxxxx

on Prolonging Bone Metastasis Free Survival in Men with Refractory Prostate Cancer.

39. A Phase 3 Extension Study to Evaluate the Safety of xxxxxxxxxxxx, in Man withHormone-Refractory Prostate Cancer.

40. Preliminary Efficacy and Safety of xxxxxxxxx in the Treatment of Hypogonadism: A 4week, Randomized, double-Blind, Placebo-Controlled, Parallel-Group Study Comparing

Daily Oral of xxxxxxxxxxx and Placebo.

September 2007 5


6/6


Publications:

1. Condyloma Acuminatum Of The Bladder And Associated Urothelial Malignancy;

Journal Of Urology, Vol. 134: 134-136, Jul, 1985

2. The Prognostic Significance Of Post-Irradiaton Biopsy Results In Patients WithProstatic Cancer; Journal Of Urology, Vol. 135 (3): 510-516, Mar, 1986

3. Extracorporal Shock Wave Lithotripsy with a transportable electrohydraulic Lithotripter:Experience with > 300 Patients, British Journal of Urology International, Vol 98-003-007,

2005

September 2007 6

jefffrankelmd

Documents